- The FDA allows the marketing of Dexcom's (NASDAQ:DXCM) Share mobile app that enables diabetics to share data from a continuous glucose monitor (CGM) in real time from an Apple mobile device thereby enabling caregivers to remotely monitor a patient's blood sugar levels.
- The Dexcom Share system displays data from the G4 Platinum CGM System via two apps: one installed on the patient's mobile device and the other installed on the mobile device of another person. The real-time data is transmitted to a web-based storage location where the app "follower" can download and display also in real time.
- The device is classified as Class II which means a premarket submission was not required.